SWAV:NSD-Shockwave Medical Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 322.61

Change

+6.54 (+2.07)%

Market Cap

USD 10.25B

Volume

1.42M

Analyst Target

USD 58.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-13.67 (-9.91%)

USD 51.34B
ALGN Align Technology Inc

-1.48 (-0.48%)

USD 23.62B
BRKR Bruker Corporation

+0.38 (+0.47%)

USD 12.93B
PODD Insulet Corporation

+2.02 (+1.23%)

USD 11.49B
MASI Masimo Corporation

+0.90 (+0.67%)

USD 7.14B
AXNX Axonics Modulation Technologie..

+0.15 (+0.23%)

USD 3.39B
IRTC iRhythm Technologies Inc

+0.64 (+0.58%)

USD 3.36B
QDEL Quidel Corporation

-0.05 (-0.13%)

USD 3.14B
LIVN LivaNova PLC

+0.43 (+0.78%)

USD 3.02B
IART Integra LifeSciences Holdings

-0.07 (-0.25%)

USD 2.64B

ETFs Containing SWAV

NBDS Neuberger Berman Disrupte.. 4.84 % 0.00 %

+0.44 (+0.09%)

USD 0.01B
GRPM Invesco S&P MidCap 400 GA.. 3.78 % 0.00 %

+0.10 (+0.09%)

USD 0.32B
PINK Simplify Exchange Traded .. 3.58 % 0.00 %

-0.04 (0.09%)

USD 0.12B
JSMD Janus Henderson Small/Mid.. 3.06 % 0.50 %

-0.02 (0.09%)

USD 0.36B
HLTH:AU VanEck Global Healthcare .. 2.59 % 0.00 %

-0.12 (0.09%)

USD 0.06B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.74 % 0.00 %

+9.90 (+0.09%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

+0.13 (+0.09%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

+0.05 (+0.09%)

N/A
SFYX SoFi Next 500 0.93 % 0.00 %

+0.09 (+0.09%)

USD 0.08B
FNY First Trust Mid Cap Growt.. 0.79 % 0.70 %

+0.34 (+0.09%)

USD 0.32B
ISCG iShares Morningstar Small.. 0.60 % 0.00 %

+0.34 (+0.09%)

USD 0.52B
FXH First Trust Health Care A.. 0.00 % 0.63 %

+0.18 (+0.09%)

USD 1.33B
JKJ iShares Morningstar Small.. 0.00 % 0.25 %

N/A

USD 0.21B
JKK iShares Morningstar Small.. 0.00 % 0.30 %

N/A

USD 0.52B
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

+0.66 (+0.09%)

USD 0.25B
ENTR ERShares Entrepreneurs ET.. 0.00 % 0.49 %

+0.44 (+0.09%)

USD 0.08B
GEND:LSE Lyxor Global Gender Equal.. 0.00 % 0.00 %

+0.10 (+0.09%)

USD 0.06B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

+0.10 (+0.09%)

USD 0.02B
VOOM:XETRA Lyxor Global Gender Equal.. 0.00 % 0.00 %

+0.10 (+0.09%)

USD 0.06B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.11 (+0.09%)

USD 0.02B
ELLE:LSE Lyxor Index Fund - Lyxor .. 0.00 % 0.00 %

+0.08 (+0.09%)

USD 0.06B
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.09 (+0.09%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 69.30% 94% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.30% 94% A 93% A
Trailing 12 Months  
Capital Gain 51.83% 88% B+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.83% 88% B+ 87% B+
Trailing 5 Years  
Capital Gain 863.88% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 863.88% 100% F 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 77.03% 93% A 94% A
Dividend Return 77.03% 93% A 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 100.03% 28% F 15% F
Risk Adjusted Return 77.00% 99% N/A 93% A
Market Capitalization 10.25B 97% N/A 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.